BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced an update to its previously reported results from an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A.  The Company plans to share the data during an oral presentation at the upcoming International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress (July 17-21).

Swedish Orphan Biovitrum AB (publ) (Sobi™) presents data at the virtual ISTH 2021, the 29th Congress of the International Society on Thrombosis and Haemostasis, 17 – 21 July 2021.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) announced four poster presentations on marzaptacog alfa (activated) (MarzAA) and dalcinanonog alfa (DalcA) at the upcoming International Society on Thrombosis and Haemostatis (ISTH) Virtual Congress being held from July 17-21, 2021.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that new data from its haemophilia A clinical programme will be presented at the virtual International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress, from 17-21 July 2021.